PAOLA DEGREGORIO: Open Payments
NPI 1720147085 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,753 in 50 payments from 16 companies in 2025. Trend: 2023 $565 · 2024 $758 · 2025 $1,753
Food & beverage: $1,753
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 7 | $280 |
| AstraZeneca Pharmaceuticals LP | 2 | $261 |
| Incyte Corporation | 2 | $253 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $229 |
| Deciphera Pharmaceuticals Inc. | 2 | $135 |
| Merck Sharp & Dohme LLC | 6 | $126 |
| Novartis Pharmaceuticals Corporation | 5 | $116 |
| ABBVIE INC. | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 3 | $68 |
| Daiichi Sankyo Inc. | 3 | $67 |
Products named: Lenvima, Stivarga, IMFINZI, QINLOCK, Pemazyre, KEYTRUDA, Zynyz, LUTATHERA.
Industry payments across NY — which companies pay providers there.
